US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

TEMA ONCOLOGY ETF

44.35

-0.2406-0.54%

Post-market: 44.450.0967+0.22%19:30 EDT

Volume:16.59K

Turnover:734.60K

Market Cap:214.67M

PE:- -

High:44.71

Open:44.71

Low:43.60

Close:44.59

52wk High:47.00

52wk Low:26.29

Shares:4.84M

Float Shares:4.84M

Volume Ratio:0.60

T/O Rate:0.34%

Dividend:0.02

Dividend Rate:0.04%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Legend Biotech Shares Rise 4.1% Premarket After Q2 Revenue Beat

THOMSON REUTERS

Legend Biotech Q2 Revenue Beats Estimates on Commercial Expansion

Legend Biotech Q2 FY26 Turns to Net Income of $33.2 Million; Revenue Rises 51.9% to $387.5 Million Year over Year

Legend Biotech Corporation - Carvykti Net Trade Sales Increase 50% in Q2 2026 to $657 Mln

THOMSON REUTERS

Legend Biotech Corporation Q2 Adjusted EPS USD 0.16 VS. Ibes Estimate USD 0.07

THOMSON REUTERS

Legend Biotech Reports Second Quarter 2026 Results and Recent Highlights

THOMSON REUTERS

After Multiple Bearish Catalysts, Legend Biotech's Stock Halved in Two Months: Value Trap or Bargain Opportunity?

BEONE MEDICINES Surges Over 4% in Morning Trading on Strategic Partnership with Revolution Medicines to Accelerate RAS Drug Development

What Does Eli Lilly (LLY) Gain From Its Oncology Push And New Funding Bet?

Simply Wall St.

Cogent Biosciences Files for USD 400 Million At-the-Market Stock Offering

Cogent Biosciences - May Offer up to $400 Mln in Common Stock Through Guggenheim Securities - SEC Filing

THOMSON REUTERS

Top News Today/Canada: Barrick Settles Newmont Dispute, Clearing Way to List Its Gold Assets

Sana Biotechnology Q2 Adjusted Loss Narrows, Beats Estimates

Bionano Genomics Q2 Revenue Rises on Increased Clinical Adoption

Cell Therapy Developer ProKidney's Q2 Operating Loss Widens as Trial Costs Rise

Metagenomi Q2 Net Loss Widens Cash Runway Seen Through 2027

Harrow Q2 Revenue Slightly Beats Estimates

Rocket Pharmaceuticals Posts Q2 Profit Helped by PRV Sale

Olema Pharmaceuticals Q2 Net Loss Widens on Higher Clinical Trial Spending

Biohaven Q2 Net Loss Narrows on Lower R&D Spend

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/CANC/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"CANC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CANC\",,,,,undefined,":{"symbol":"CANC","market":"US","secType":"STK","nameCN":"TEMA ONCOLOGY ETF","latestPrice":44.3533,"timestamp":1787601600000,"preClose":44.5939,"halted":0,"volume":16589,"hourTrading":{"tag":"盘后","latestPrice":44.45,"preClose":44.3533,"latestTime":"19:30 EDT","volume":12,"amount":532.7231,"timestamp":1787614204814,"change":0.0967,"changeRate":0.00218,"amplitude":0},"delay":0,"changeRate":-0.005395356764041732,"floatShares":4839999,"shares":4839999,"eps":0,"marketStatus":"Closed","change":-0.2406,"latestTime":"08-24 16:00:00 EDT","open":44.71,"high":44.71,"low":43.6,"amount":734600.23593,"amplitude":0.024891,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787644800000},"marketStatusCode":5,"adr":0,"listingDate":1692158400000,"exchange":"NASDAQ","adjPreClose":44.5939,"sharesOutstanding":4310000,"nav":44.5,"aum":215380000,"dividendRate":0.000442,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":44.9,"preClose":44.5939,"latestTime":"08:16 EDT","volume":125,"amount":5612.5,"timestamp":1787573813929,"change":0.3061,"changeRate":0.006864,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":44.45,"preClose":44.3533,"latestTime":"19:30 EDT","volume":12,"amount":532.7231,"timestamp":1787614204814,"change":0.0967,"changeRate":0.00218,"amplitude":0},"volumeRatio":0.602794},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CANC\",,,,,undefined,":{"symbol":"CANC","floatShares":4839999,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.602794,"shares":4839999,"dividePrice":0.0196,"high":44.71,"amplitude":0.024891,"preClose":44.5939,"low":43.6,"week52Low":26.29,"pbRate":"--","week52High":47,"institutionHeld":0,"latestPrice":44.3533,"eps":0,"divideRate":0.000442,"volume":16589,"delay":0,"ttmEps":0,"open":44.71,"prevYearClose":34.7203,"prevWeekClose":44.5939,"prevMonthClose":40.5957,"prevQuarterClose":41.24,"fiveDayClose":43.1663,"twentyDayClose":41.1012,"sixtyDayClose":38.3044},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CANC\",params:#limit:5,,,undefined,":[{"date":"2025-12-10","symbol":"CANC","amount":0.0195905,"announcedDate":"2025-12-09","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-10","defaultRemindTime":1765377000000,"name":"TEMA ONCOLOGY ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-11","payableDate":"2025-12-10","currency":"USD","dateTimestamp":1765342800000,"payDate":"2025-12-11"},{"date":"2024-12-11","symbol":"CANC","amount":0.72827,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-11","defaultRemindTime":1733927400000,"name":"TEMA ONCOLOGY ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-12","payableDate":"2024-12-11","currency":"USD","dateTimestamp":1733893200000,"payDate":"2024-12-12"},{"date":"2023-12-13","symbol":"CANC","amount":0.149112,"announcedDate":"2023-12-12","type":"dividend","market":"US","newRecordDate":"2023-12-14","defaultRemindTime":1702477800000,"name":"TEMA ONCOLOGY ETF","recordDate":"2023-12-15","payableDate":"2023-12-14","currency":"USD","dateTimestamp":1702443600000,"payDate":"2023-12-15"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CANC\",market:\"US\",,,undefined,":[{"executeDate":"2023-12-13","recordDate":"2023-12-14","paymentDate":"2023-12-15","value":0.149112,"currency":"USD"},{"executeDate":"2024-12-11","recordDate":"2024-12-11","paymentDate":"2024-12-12","value":0.72827,"currency":"USD"},{"executeDate":"2025-12-10","recordDate":"2025-12-10","paymentDate":"2025-12-11","value":0.0195905,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CANC\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CANC\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2658992947","title":"Legend Biotech Shares Rise 4.1% Premarket After Q2 Revenue Beat","url":"https://stock-news.laohu8.com/highlight/detail?id=2658992947","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658992947?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:15","pubTimestamp":1786446949,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nFWN4480NL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","BK4585","MEDI","LEGN","BK4139","MEMS","BK4588","CANC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658699254","title":"Legend Biotech Q2 Revenue Beats Estimates on Commercial Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2658699254","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658699254?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:09","pubTimestamp":1786446570,"startTime":"0","endTime":"0","summary":"Legend Biotech Q2 revenue beats estimates on commercial expansionOverviewCell therapy company's Q2 revenue rose sharply, beating analyst expectationsAdjusted EPS for Q2 beat analyst expectations, refl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL1N4480DK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU1989771016.USD","LEGN","BK4139","LU0096364046.USD","LU0985481810.HKD","LU0267386448.USD","LU0237698245.USD","LU2596442595.SGD","IE0002141913.USD","IHE","LU0225284248.USD","LU1291159041.SGD","LU1323610961.USD","LU1670711040.USD","LU1670710588.SGD","BK4534","LU0868494617.USD","IE0009355771.USD","BK4559","LU1983299246.USD","FTXH","LU2242646821.SGD","LU1868837300.USD","LU1585245621.USD","LU1571399168.USD","MEDI","BBIO","LU2242652126.USD","LU1718418525.SGD","LU1074936037.SGD","BK4505","LU0321505868.SGD","LU1868836757.USD","LU0114720955.EUR","LU1868836914.USD","CANC","LU0456855351.SGD","BK4585","MEMS","BMY","PROK","IE00BFTCPJ56.SGD","LU1670711123.USD","LU0321505439.SGD","LU1670710661.SGD","BK4007","LU1032466523.USD","LU1261432733.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658992582","title":"Legend Biotech Q2 FY26 Turns to Net Income of $33.2 Million; Revenue Rises 51.9% to $387.5 Million Year over Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2658992582","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658992582?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:07","pubTimestamp":1786446478,"startTime":"0","endTime":"0","summary":"Legend Biotech Q2 FY26 turns to net income of $33.2 million; revenue rises 51.9% to $387.5 million year over yearLegend Biotech posted IFRS net income of $33.2 million, swinging from a loss, on total ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL9tmbRj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CANC","BK4585","MEMS","BK4588","MEDI","BK4139","LEGN","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658947969","title":"Legend Biotech Corporation - Carvykti Net Trade Sales Increase 50% in Q2 2026 to $657 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2658947969","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658947969?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:00","pubTimestamp":1786446004,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nPLX818D8T:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","BK4505","BK4139","CANC","MEDI","MEMS","LEGN","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658299405","title":"Legend Biotech Corporation Q2 Adjusted EPS USD 0.16 VS. Ibes Estimate USD 0.07","url":"https://stock-news.laohu8.com/highlight/detail?id=2658299405","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658299405?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:00","pubTimestamp":1786446004,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nPLX818D8T:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","BK4588","BK4139","CANC","LEGN","MEMS","MEDI","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658199442","title":"Legend Biotech Reports Second Quarter 2026 Results and Recent Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2658199442","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658199442?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:00","pubTimestamp":1786446004,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nTUA47MYCS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MEDI","BK4588","CANC","MEMS","BK4585","BK4139","BK4505","LEGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183064015","title":"After Multiple Bearish Catalysts, Legend Biotech's Stock Halved in Two Months: Value Trap or Bargain Opportunity?","url":"https://stock-news.laohu8.com/highlight/detail?id=1183064015","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183064015?lang=en_us&edition=fundamental","pubTime":"2026-08-11 18:11","pubTimestamp":1786443066,"startTime":"0","endTime":"0","summary":"A sharp 40% rally that seemed to signal a new valuation upswing instead marked the final chapter of the previous rebound. After spending two months pushing its share price back to a high of $37.50,...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LEGN","GLL","BK4139","SGUmain","IAUI","JDST","SGOL","IGLD","159831","SGCmain","UYM","RING","DBC","BGLD","GDXD","GOLY","GLD","BK4207","PALL","518880","GOAU","UGL","XME","GLDM","BK4535","DGZ","DULL","BAR","YGLD","CEF","CANC","DZZ","GDXU","GCmain","1OZmain","BK4504","GDX","BTGD","GBUG","GLTR","PHYS","GDXJ","DGP","MGCmain","SGDM","BK4585","OUNZ","IAUM","GLDY","GDXY","IAU","159934","DUST","MEMS","BEGS","KGLD","USG","AAAU","PICK","NUGT","MEDI","SHNY","FAAR","FGDL","JNUG","QOmain","BK4588","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123475942","title":"BEONE MEDICINES Surges Over 4% in Morning Trading on Strategic Partnership with Revolution Medicines to Accelerate RAS Drug Development","url":"https://stock-news.laohu8.com/highlight/detail?id=1123475942","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123475942?lang=en_us&edition=fundamental","pubTime":"2026-08-11 09:46","pubTimestamp":1786412777,"startTime":"0","endTime":"0","summary":"BEONE MEDICINES (06160) saw its shares surge more than 4% during early trading hours, before settling at a 2.72% gain to 219 Hong Kong dollars, with a trading volume of 297 million Hong Kong...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD","KURE","BBH","BK1500","BK1161","06160","LU1719994722.HKD","BK1588","LU0889565916.HKD","CANC","LU1969619763.USD","LU1770034418.SGD","IE00BJT1NW94.SGD","LU1251922891.USD","BK4585","BK0239","BK4139","IE0002141913.USD","LU0307460666.USD","LU1303224171.USD","KCAI","BK1583","LU0228659784.USD","IE00BFTCPJ56.SGD","LU0828237510.HKD","BK4588","IE00B2B36J28.USD","IE0009355771.USD","688235","PTH","IE00B4R5TH58.HKD","ONC","IE0009354923.USD","IE00BJJMRZ35.SGD","IDNA","LU2328871848.SGD","LU0109394709.USD","LU0588546209.SGD","BK4526","VXUS","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658963913","title":"What Does Eli Lilly (LLY) Gain From Its Oncology Push And New Funding Bet?","url":"https://stock-news.laohu8.com/highlight/detail?id=2658963913","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658963913?lang=en_us&edition=fundamental","pubTime":"2026-08-11 08:38","pubTimestamp":1786408688,"startTime":"0","endTime":"0","summary":"Eli Lilly (NYSE: LLY) has entered a new clinical trial collaboration with Amplia Therapeutics to test a novel drug combination in non-small cell lung cancer.\nThe move extends Eli Lilly's precision oncology efforts following Breakthrough Therapy designation for its KRAS G12C inhibitor in a rare pancreatic cancer subset.\nEli Lilly also joined Remedium Bio's Series A financing, adding exposure to early-stage durable protein therapeutics beyond its existing metabolic disease portfolio.\n\nThis...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/285467-main-header/1756214710679","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/285467-main-header/1756214710679"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-lly/eli-lilly/news/what-does-eli-lilly-lly-gain-from-its-oncology-push-and-new","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-lly/eli-lilly/news/what-does-eli-lilly-lly-gain-from-its-oncology-push-and-new","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0225283273.USD","LU2468319806.SGD","IE00BJT1NW94.SGD","LU1057294990.SGD","IE00BN29S564.USD","LU0823434740.USD","IE00BKDWB100.SGD","LU1093756325.SGD","IE00BK4W5L77.USD","LU1623119135.USD","LU1712237335.SGD","SG9999001176.SGD","SG9999015986.USD","SGXZ81514606.USD","LU2237443978.SGD","LU0672654240.SGD","LU2461242641.AUD","SG9999018865.SGD","LU2168564065.EUR","LU0320765992.SGD","LU2357305700.SGD","LU2462591350.SGD","IE0002141913.USD","IE00B4R5TH58.HKD","LU0210536198.USD","IE00BFTCPJ56.SGD","LU2602419157.SGD","LU2023250504.SGD","LU0097036916.USD","LU0323591593.USD","ELIL","LLII","LU1267930730.SGD","PJP","LU2168564149.EUR","LU2746668461.USD","LU0316494557.USD","LU0256863811.USD","IXJ","LU2462157665.USD","LU1323610961.USD","LU2213496289.HKD","LU0266013472.USD","LU1023059063.AUD","SG9999001176.USD","LU1917777945.USD","LU2023251221.USD","LU2471134523.USD","IE0005OL40V9.USD","LLYZ","VHT","LU1551013425.SGD","IE00BKPKM429.USD","LU2028103732.USD","LU2211815571.USD","IE00BJLML261.HKD","LU1035775433.USD","BK4007","LU2896262040.SGD","PPH","SG9999015952.SGD","LU0122379950.USD","IE00B4JS1V06.HKD","LU0198837287.USD","LU0094547139.USD","TMED","LU2237443895.HKD","LU0708995401.HKD","LU2471134879.HKD","LU1720051108.HKD","IE0001KFT4U8.USD","LU2552382215.SGD","LU0106261372.USD","LU0882574139.USD","LU1868836757.USD","LU2456880835.USD","SG9999015978.USD","SGXZ51526630.SGD","MHIP","LU1291159041.SGD","LU2089984988.USD","IE0009355771.USD","LU0432979614.USD","LU0882574055.USD","LU2361044865.SGD","LU0823434583.USD","IE00BWXC8680.SGD","LU0417517546.SGD","LU0466842654.USD","LU2746668974.SGD","LU0174119429.USD","XLV","LU0203201768.USD","AGNG","LU1629891620.HKD","IE00BJJMRY28.SGD","SG9999018857.SGD","LU0058720904.USD","LU0061475181.USD","MEDI","LU1868836591.USD","LU2237443382.USD","LU2271345857.HKD","LU0203202063.USD","SG9999014880.SGD","LU2087625088.SGD","LU2324357040.USD","LU1551013342.USD","LU0943347566.SGD","LU0109391861.USD","LU0640476718.USD","FHLC","LU0823416689.USD","LU2756315318.SGD","LU0345770993.USD","LU0353189680.USD","IE00B7KXQ091.USD","LU0964807845.USD","LU2361044949.HKD","LU0385154629.USD","LU0320765059.SGD","LLYX","IE00BK4W5M84.HKD","LU2111349929.HKD","CURE","LU0820561909.HKD","LU1093756168.USD","LU1974910355.USD","SG9999014914.USD","IE0004445239.USD","LU0683600562.USD","SG9999014906.USD","LU0114720955.EUR","TRUH","IE00B775H168.HKD","LU0234572021.USD","LU0786609619.USD","SGXZ57979304.SGD","JDOC","LU0158827781.USD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU0889565916.HKD","LU2168564222.USD","LU0238689110.USD","BK4599","LU2491050071.SGD","LU0471298694.HKD","LU1232071149.USD","CANC","IE00BFSS7M15.SGD","LU1988902786.USD","LU1983299246.USD","SG9999013999.USD","LU1868836914.USD","LU1868837300.USD","SGXZ31699556.SGD","LU1280957306.USD","LU1061106388.HKD","SGXZ99366536.SGD","LU1064131342.USD","LU1145028129.USD","LU0256863902.USD","SG9999017495.SGD","LU2063271972.USD","LU2089283258.USD","LU2552382058.USD","BK4588","IE00BFSS8Q28.SGD","LU2750360641.GBP","LU2756315664.SGD","LU2264538146.SGD","LU1127390331.HKD","LU2491050154.USD","LU0820562030.AUD","LU2237443622.USD","IE0004445015.USD","LU0689472784.USD","LU1979441026.SGD","LU0096364046.USD","ILDR","LU1366192091.USD","LU2265009873.SGD","LU0109394709.USD","LU2168563687.JPY","LU2417539215.USD","LU1069344957.HKD","LU1814569148.SGD","LU0006306889.USD","LU0345770308.USD","LU2471134796.USD","LU0289739699.SGD","LLY","LU2108987350.USD","LU2237443465.HKD","BK4534","IE00B1XK9C88.USD","LU1868837136.USD","LU2089284900.SGD","HRTS","LU0471298777.SGD","LU0456855351.SGD","LU2491049909.HKD","LU0158827948.USD","IE00B1BXHZ80.USD","OZEM","LU0820561818.USD","LU0353189763.USD","LU0354030511.USD","LU0133085943.USD","BK4581","IE00BJJMRX11.SGD","LU0787776722.HKD","IYH","BK4585","LU2112291526.USD","LU1804176565.USD","LU1989771016.USD","LU2237443549.SGD","RXL","BK4533","IHE","SG9999014898.SGD","LU0079474960.USD","LU2237438978.USD","LU2750360997.AUD","LU1548497426.USD","LU2552382132.HKD","LU2106854487.HKD","BK4516","LU2023250330.USD","LU2168564495.EUR","LU2360106947.USD","LU2471134952.CNY","WDNA","LU2236285917.USD","THNR","ELIS","LU2361045086.USD","GB00BDT5M118.USD","LU0354030438.USD","MEDX","FTXH","GDOC","LU1720051017.SGD","SG9999015945.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658339952","title":"Cogent Biosciences Files for USD 400 Million At-the-Market Stock Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2658339952","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658339952?lang=en_us&edition=fundamental","pubTime":"2026-08-11 05:20","pubTimestamp":1786396815,"startTime":"0","endTime":"0","summary":"Cogent Biosciences files for USD 400 million at-the-market stock offeringCogent Biosciences set an at-the-market equity offering of up to USD 400 million under its sales agreement with Guggenheim Secu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nNDL5kPmbQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","CANC","COGT","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658952825","title":"Cogent Biosciences - May Offer up to $400 Mln in Common Stock Through Guggenheim Securities - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2658952825","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658952825?lang=en_us&edition=fundamental","pubTime":"2026-08-11 05:18","pubTimestamp":1786396717,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nFWN4471SE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","CANC","COGT","BK4139","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658951980","title":"Top News Today/Canada: Barrick Settles Newmont Dispute, Clearing Way to List Its Gold Assets","url":"https://stock-news.laohu8.com/highlight/detail?id=2658951980","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658951980?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:33","pubTimestamp":1786393980,"startTime":"0","endTime":"0","summary":"HEADLINESBarrick Mining Settles Newmont Nevada Dispute for $1.95 Billion, Clearing Way to List its Gold AssetsBarrick Mining has settled a long-standing dispute with rival Newmont over their Nevada op","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEMS","IMUX","NVRI","CAH","AVXL","BK4123","SYPR","LEGN","BK4127","CRIS","FLOC","DOMH","AMTM","WHF","TNGX","LVWD","RXT","ACCS","BK4167","DRIO","TCRX","APRE","MASS","BK4023","BWEN","SLSN","CANC","VSTS","ARMK","BSIN","KLXE","VERA","MIDD","BK4175","STIM","BK4179","OBIO","HBIO","REFI","IMNN","MEDI","JBI","SG9999001440.SGD","BK4109","IE00B3S45H60.SGD","LU0154236417.USD","PESI","GHI","SLAB","LU0240877869.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658951818","title":"Sana Biotechnology Q2 Adjusted Loss Narrows, Beats Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2658951818","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658951818?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:24","pubTimestamp":1786393458,"startTime":"0","endTime":"0","summary":"Sana Biotechnology Q2 adjusted loss narrows, beats estimatesOverviewCell therapy developer's Q2 adjusted loss per share beat analyst expectationsQ2 adjusted net loss also beat analyst expectationsComp","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL1N4470W1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","CANC","BK4139","SANA","BK4505","COGT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658951894","title":"Bionano Genomics Q2 Revenue Rises on Increased Clinical Adoption","url":"https://stock-news.laohu8.com/highlight/detail?id=2658951894","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658951894?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:24","pubTimestamp":1786393456,"startTime":"0","endTime":"0","summary":"Bionano Genomics Q2 revenue rises on increased clinical adoptionOverviewGenome analysis solutions provider's Q2 revenue rose 21% yr/yr to $8.2 mlnGross margin for Q2 improved to 53% from 52% a year ea","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL1N4470WJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QTRX","BNGO","BK4575","COGT","BK4121","LFSC","CANC","BK4505","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658518889","title":"Cell Therapy Developer ProKidney's Q2 Operating Loss Widens as Trial Costs Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2658518889","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658518889?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:22","pubTimestamp":1786393334,"startTime":"0","endTime":"0","summary":"Cell therapy developer ProKidney's Q2 operating loss widens as trial costs riseOverviewU.S. cell therapy developer's Q2 operating expenses rose, driven by clinical study and manufacturing costsNet los","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL1N4470W0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","BK4505","CANC","PROK","COGT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658959032","title":"Metagenomi Q2 Net Loss Widens Cash Runway Seen Through 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2658959032","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658959032?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:21","pubTimestamp":1786393289,"startTime":"0","endTime":"0","summary":"Metagenomi Q2 net loss widens cash runway seen through 2027OverviewGenome editing firm's Q2 net loss widened to $27.5 mln, loss per share was $0.73Company ended Q2 with $120.7 mln in cash, expects run","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL1N4470VT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COGT","TBPH","MGX","CANC","BK4007","LFSC","BK4505","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658295927","title":"Harrow Q2 Revenue Slightly Beats Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2658295927","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658295927?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:19","pubTimestamp":1786393164,"startTime":"0","endTime":"0","summary":"Harrow Q2 revenue slightly beats estimatesOverviewOphthalmic drug maker's Q2 revenue rose 11% yr/yr, slightly beating analyst expectationsCompany posted net loss per share of $0.46, down from profit l","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL1N4470WT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CANC","BK4139","HRTX","BK4557","LFSC","BK4505","HROW","BK4007","COGT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658895955","title":"Rocket Pharmaceuticals Posts Q2 Profit Helped by PRV Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2658895955","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658895955?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:10","pubTimestamp":1786392651,"startTime":"0","endTime":"0","summary":"Rocket Pharmaceuticals posts Q2 profit helped by PRV saleOverviewUS biotech firm reported Q2 net income after KRESLADI approval and PRV saleR&D and G&A expenses fell yr/yr due to lower headcount and c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL1N4470UW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COGT","CANC","BK4139","BK4007","BK4121","LFSC","TBPH","QTRX","RCKT","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658959530","title":"Olema Pharmaceuticals Q2 Net Loss Widens on Higher Clinical Trial Spending","url":"https://stock-news.laohu8.com/highlight/detail?id=2658959530","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658959530?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:10","pubTimestamp":1786392606,"startTime":"0","endTime":"0","summary":"Olema Pharmaceuticals Q2 net loss widens on higher clinical trial spendingOverviewUS biopharmaceutical firm's Q2 net loss widened yr/yr due to higher clinical development spendingCompany completed enr","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL1N4470V3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CANC","BK4139","LFSC","OLMA","BK4505","COGT","TBPH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658959562","title":"Biohaven Q2 Net Loss Narrows on Lower R&D Spend","url":"https://stock-news.laohu8.com/highlight/detail?id=2658959562","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658959562?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:09","pubTimestamp":1786392543,"startTime":"0","endTime":"0","summary":"Biohaven Q2 net loss narrows on lower R&D spendOverviewU.S. biopharma firm's Q2 net loss narrowed yr/yr on lower R&D and preclinical spendingQ2 operating expenses fell sharply after strategic repriori","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL1N4470V8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CANC","LFSC","BK4139","BK4007","LU1093756325.SGD","COGT","LU1093756168.USD","BHVN","TBPH","BK4505"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":7,"totalSize":200,"code":"91000000","status":"200"}]}}